From understanding diseases to drug design: can artificial intelligence bridge the gap?

被引:9
|
作者
Pushkaran, Anju Choorakottayil [1 ]
Arabi, Alya A. [1 ]
机构
[1] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Biochem & Mol Biol, POB 15551, Al Ain, U Arab Emirates
关键词
Artificial intelligence; Machine learning; Disease identification; Drug discovery; TARGET IDENTIFICATION; DIABETIC-RETINOPATHY; NEURAL-NETWORKS; DEEP; CLASSIFICATION; VALIDATION; PREDICTION; ALGORITHM; DISCOVERY; CANCER;
D O I
10.1007/s10462-024-10714-5
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Artificial intelligence (AI) has emerged as a transformative technology with significant potential to revolutionize disease understanding and drug design in healthcare. AI serves as a remarkable accelerating tool that bridges the gap between understanding diseases and discovering drugs. Given its capacity in the analysis and interpretation of massive amounts of data, AI is tremendously boosting the power of predictions with impressive accuracies. This allowed AI to pave the way for advancing all key stages of drug development, with the advantage of expediting the drug discovery process and curbing its costs. This is a comprehensive review of the recent advances in AI and its applications in drug discovery and development, starting with disease identification and spanning through the various stages involved in the drug discovery pipeline, including target identification, screening, lead discovery, and clinical trials. In addition, this review discusses the challenges that arise during the implementation of AI at each stage of the discovery process and provides insights into the future prospects of this field.
引用
收藏
页数:39
相关论文
共 50 条
  • [31] UNDERSTANDING DESIGN - ARTIFICIAL-INTELLIGENCE AS AN EXPLANATORY PARADIGM
    DASGUPTA, S
    SADHANA-ACADEMY PROCEEDINGS IN ENGINEERING SCIENCES, 1994, 19 : 5 - 21
  • [32] Artificial intelligence and Italian culture: an understanding of how artificial intelligence can transform the radiation therapy landscape
    De Felice, Francesca
    MEDICAL ONCOLOGY, 2023, 40 (10)
  • [34] HOW CAN ARTIFICIAL INTELLIGENCE IMPACT THE MANAGEMENT OF MUSCULOSKELETAL DISEASES?
    Dimai, H. P.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S35 - S36
  • [35] FoCo system: a tool to bridge the domain gap between fashion and artificial intelligence
    Zou, Xingxing
    Wong, Wai Keung
    Gao, Can
    Zhou, Jie
    INTERNATIONAL JOURNAL OF CLOTHING SCIENCE AND TECHNOLOGY, 2019, 31 (05) : 630 - 643
  • [36] Artificial Intelligence, Drug Development and Frameworks: An Opportunity to Enhance Understanding
    Beninger, Paul
    CLINICAL THERAPEUTICS, 2024, 46 (08) : 595 - 596
  • [37] Potential of Artificial Intelligence to Accelerate Drug Development for Rare Diseases
    Napolitano, Giulio
    Has, Canan
    Schwerk, Anne
    Yuan, Jui-Hung
    Ullrich, Carsten
    PHARMACEUTICAL MEDICINE, 2024, 38 (02) : 79 - 86
  • [38] Potential of Artificial Intelligence to Accelerate Drug Development for Rare Diseases
    Giulio Napolitano
    Canan Has
    Anne Schwerk
    Jui-Hung Yuan
    Carsten Ullrich
    Pharmaceutical Medicine, 2024, 38 : 79 - 86
  • [39] Generative artificial intelligence for small molecule drug design
    Kanakala, Ganesh Chandan
    Devata, Sriram
    Chatterjee, Prathit
    Priyakumar, Udaykumar Deva
    CURRENT OPINION IN BIOTECHNOLOGY, 2024, 89
  • [40] Artificial intelligence in peptide-based drug design
    Zhai, Silong
    Liu, Tiantao
    Lin, Shaolong
    Li, Dan
    Liu, Huanxiang
    Yao, Xiaojun
    Hou, Tingjun
    DRUG DISCOVERY TODAY, 2025, 30 (02)